Clinical academic pharmacists sit at the intersection of frontline healthcare and cutting-edge research, turning evidence into everyday practice.
This page highlights how their work transforms patient care, influences policy, drives service innovation, and shapes the future of pharmacy as a research-active profession.
Examples of impact
ActMed Study
Led in part by clinical academic pharmacist Dr Zoe Edwards, the ActMed study explored how patients and families access essential palliative medicines at home. The research uncovered delays and safety risks that could be reduced through stronger pharmacist involvement in hospice care. Its findings were cited in the House of Lords during the January 2020 second reading of the Access to Palliative Care Bill, demonstrating how clinical academic pharmacists can translate frontline research into national policy and safer, more responsive end-of-life care.
IMPACCT Study
This study examined how community pharmacists can improve the experience of people living with cancer. Dr Zoe Edwards was a key researcher, showing how pharmacists help patients manage symptoms, navigate treatment and access timely support close to home. The findings influenced the Royal Pharmaceutical Society’s 2020 report, Utilising Community Pharmacists to Support People with Cancer, advocating for a more active pharmacy role in cancer care.
STOPP/START Criteria
Consensus-validated criteria for reviewing medicines in older adults established a practical, evidence-based approach to identifying inappropriate prescribing and missed treatments. Pharmacists’ involvement ensured the criteria were applicable in everyday practice, influencing national prescribing policy and guidance and improving safety for older patients across the NHS.
PINCER Study
This pharmacist-led, IT-supported intervention helped identify and reduce prescribing and monitoring errors in general practice. Combining computerised searches with pharmacist-delivered feedback, the study achieved meaningful reductions in hazardous prescribing and informed national medicines-optimisation policy, including adoption in NICE guidance.